Skip to main content

After ‘transformative’ year, Roivant aims to challenge bigger rivals in inflammation and immunology

Roivant shares gain more than 10% after narrower-than-expected quarterly loss.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.